Vaxxas secures funding for clinical trials of nanopatch delivered vaccines

update: WHO says tech like Nanopatch can help get vaccines to the people that need them

Vaxxas raises $20m for nanopatch vaccine trials

By Gareth Macdonald

Vaccine patch firm Vaxxas has raised $20m (€17.7m) to fund clinical development of its pipeline of influenza, polio and bacterial infection vaccines.

GSK is preparing 10,000 doses as a Phase I trial begins.

GSK begins manufacturing 10,000 Ebola vaccine doses for WHO

By Zachary Brennan

As more than half a dozen companies are now vying to help treat and vaccinate Ebola victims in West Africa, where nearly 3,000 people have died from the illness, GlaxoSmithKline is taking the lead in getting product manufactured.

Snip, snip: CRISPR-Cas allows scientists to cut out (and insert) genes.

Patents and profits: the battle to own CRISPR

By Fiona BARRY

CRISPR, the gene-editing technology that could revolutionise biologics, is set to become a patent battleground as companies vie over who owns the tool and its products, says an intellectual property expert.

Follow us


View more